Abstract
Background Dogs with immune‐mediated thrombocytopenia (ITP) are at risk of hemorrhage when platelet count is P = .51). Median hospitalization time for all dogs that survived to discharge was 4 days and not different between groups (P = .29). Seven of 10 dogs in the hIVIG group and 10 of 10 in the VINC group survived to discharge. Survival analysis did not identify any significant difference between the groups at discharge, 6 months, and 1 year after entry into the study. No adverse effects were reported in either group. Conclusions and Clinical Importance Vincristine should be the first‐line adjunctive treatment for the acute management of canine ITP because of lower cost and ease of administration compared with human intravenous immunoglobulin (hIVIG).

This publication has 13 references indexed in Scilit: